Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17 therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F, have been shown to be functionally dysregulated in certain human immune-mediated inflammatory diseases such as pso...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Ralph, Maroof, Asher, Baker, Terry, Lawson, Alastair D. G., Oliver, Ruth, Paveley, Ross, Rapecki, Steve, Shaw, Stevan, Vajjah, Pavan, West, Shauna, Griffiths, Meryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473305/
https://www.ncbi.nlm.nih.gov/pubmed/32973785
http://dx.doi.org/10.3389/fimmu.2020.01894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473305/
https://www.ncbi.nlm.nih.gov/pubmed/32973785
http://dx.doi.org/10.3389/fimmu.2020.01894

Ejemplares similares